Hemorrhoid Master Ointment
NDC Package 63742-045-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Hemorrhoid Master (lidocaine, phenylephrine hcl) ointment is uses■ For the temporary relief of local and anorectal itching and discomfort associated with anorectal disorders and anorectal inflammation.■ For the temporary relief of pain, burning and soreness.■ Temporarily shrinks hemorrhoidal tissue.■ Temporarily reduces the swelling associated with irritation in hemorrhoids and other anorectal disorders. This formulation utilizes a ointment delivery system. Marketed by Clinical Resolution Laboratory, Inc., this product is identified by NDC 63742-045 and is authorized under FDA application M015.

Identification & Billing

NDC Package Code
63742-045-01
Package Description
45 g in 1 TUBE, WITH APPLICATOR
Product Code
11-Digit Billing Format
63742004501
RxNorm Crosswalk
  • RxCUI: 2673304 - lidocaine 4 % / phenylephrine HCl 0.25 % Rectal Ointment
  • RxCUI: 2673304 - lidocaine 0.04 MG/MG / phenylephrine hydrochloride 0.0025 MG/MG Rectal Ointment

Clinical Specifications

Proprietary Name
Hemorrhoid Master
Non-Proprietary Name
Lidocaine, Phenylephrine Hcl
Substance Name
Lidocaine; Phenylephrine Hydrochloride
Dosage Form
Ointment - A semisolid3 dosage form, usually containing <20% water and volatiles5 and >50% hydrocarbons, waxes, or polyols as the vehicle. This dosage form is generally for external application to the skin or mucous membranes.
Administration Route
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Usage Information
Uses■ For the temporary relief of local and anorectal itching and discomfort associated with anorectal disorders and anorectal inflammation.■ For the temporary relief of pain, burning and soreness.■ Temporarily shrinks hemorrhoidal tissue.■ Temporarily reduces the swelling associated with irritation in hemorrhoids and other anorectal disorders.

Regulatory & Marketing

Labeler Name
Clinical Resolution Laboratory, Inc.
Product Type
Human Otc Drug
FDA Application #
M015
Marketing Category
OTC MONOGRAPH DRUG -
Start Marketing Date
11-01-2019
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 63742-045-01 identifies a specific commercial package of 45 g in 1 tube, with applicator of Hemorrhoid Master, a human over the counter drug labeled by Clinical Resolution Laboratory, Inc.. This ointment is formulated for topical use and contains lidocaine; phenylephrine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Clinical Resolution Laboratory, Inc. on November 01, 2019. The current certification is valid through December 31, 2026.

How is this Clinical Resolution Laboratory, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 63742004501. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
63742-045-01
11-Digit CMS (5-4-2)
63742-0045-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.